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Abstract 
The causative agent of ASF is a large deoxyvirus that has been assigned to Asfarviridae family. Previous studies have 
shown that ASFV p54 and p30 are essential viral proteins involved in the early steps of viral infection, whereas the 
adsorption of ASFV to susceptible cells is mediated by the structural virus protein p12, located within the outer 
envelope of the virion. It is believed that the lack of efficient ASFV vaccines might be due to unique molecular and 
biological properties of ASFV proteins responsible for virus–cell interactions: p30, p54 and p12. 
 
In this report, we describe the effect of in vitro blockage of ASF virus–cell interactions mediated by p54, p30 and 
p12. Computer analysis of p54 gene sequences of different ASFV field strains form GenBank was performed. 
According to this analysis ASFV viruses were distributed in several groups matching their serotype classification 
developed at our institute earlier. 
 
Immunization of rabbits with recombinant p54, p12 or p30 proteins induced antibodies which inhibited virus 
attachment or internalization. The serum of rabbits immunized with p54 of Magadi strain prevented virus attachment 
of Magadi group viruses only. In contrast, the serum from rabbits immunized with p30 (Magadi strain) rendered an in
vitro inhibition of different ASFV groups replication.  
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1. Introduction 
ASFV is a large icosahedral DNA virus (Fig. 1), replicates in cell cytoplasm. Virion of ASFV includes 
linear dsDNA genome 170-190 kbp. ASFV is a sole member of Asfarviridae and only DNA Arbovirus 
which infects and persists in soft ticks and members of Suidae family. 
 
(a)    (b)     (c)   
   
Fig. 1. ASFV virion structure and effect of haemadsorbtion  on erythrocytes surface (a, b and c). Primary porcine blood macrophage 
cell cultures (PBMC) were infected with Kongo-73 and processed at 18 hpi for conventional Epon embedding. Note that the overall 
appearance of the viral factories (c). When compared in detail interaction virions with erythrocytes surface observed two stages: the 
primary contact (a) and full covered by erythrocyte surface (b). The arrangement virion p54, p30 and p12 indicate by arrowheads in 
panel A. Bars, 200 nm. 
African swine fever virus (ASFV produces different forms of disease, ranging from highly lethal 
(100%) to subclinical [7]. African swine fever is characterized by edema, ascites and haemorrhage, 
replication and spread within mononuclear-phagocytic system, long-term persistent (avirulent strains 
induce case latent) infection. Domestic and wild pigs are susceptible. There are waste natural reservoirs 
represented by wart hogs and soft ticks of the Ornithodoros genus at Africa [ 8 ]. 
 
Currently, there is no vaccine against ASF. Experimentally, complete protection of pigs against 
homologous virus challenge was only conferred by inoculation of cell culture attenuated viruses [ 9 ]. A 
nonhemadsorbing African swine fever virus isolate ASFV/NH/P68 provides a model for delineating the 
protective immune response. 
 
Analyses of cell extracts revealed presence of more than 150 viral proteins synthesized on different 
steps of ASFV life cycle [ 15 ]. p30 and p54 are externally located virus structural proteins [ 5, 12 ] 30 
and 25 kDa, encoded by the virus genes CP204L and E183L, respectively [ 1, 17 ]. ASFV p54 is an 
essential virus protein involved in the early steps of viral infection and the adsorption of ASFV to 
susceptible cells. The ASFV virus protein p12 is involved in virus attachment to the host cell and located 
within the outer envelope of the virions [ 2 ]. 
 
Gomez-Puertas P. et al. (1998) [ 6 ]  demonstrated that African swine fever virus proteins p54 and p30 
are involved in two distinct step of virus attachment and both contribute to the antibody mediated 
protective immune responses. Barderas M.G. et al.(2001) [ 4 ] have investigated the role of the 
neutralizing chimeric protein 54/30 in the early stages of ASF virus infection and its role in the protective 
immune response. To analyze the immune response induced by chimeric protein 54/30 involved in ASF 
virus–cell interactions, groups of pigs were immunized with the recombinant chimeric protein 54/30. The 
immunized pigs were protected from virus challenge. 
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The failure of conventional approaches to generate an efficient ASFV vaccine, along with viral 
mechanisms of immune system evasion prompted studies towards identification of ASFV proteins genes 
possibly involved in such mechanisms. Therefore the significance of virus–cell interactions inhibition 
mediated by Abs to ASFV p54, p30 and p12 in vitro was investigated. 
2. Materials and methods 
2.1. Cells and viruses 
CV-1, Vero and PPK-66b cell lines were used for the adaptation of wild-type viruses. Primary porcine 
blood macrophage cell cultures (PBMC) were isolated from defibrinated swine blood. Briefly, heparin-
treated swine blood was incubated at 37°C for 1 h to allow sedimentation of the erythrocyte fraction. 
Mononuclear leukocytes were separated by flotation over a Ficoll-Paque (Pharmacia, Piscataway, N.J.). 
The monocyte-macrophage cell fraction was cultured in Dulbecco's modified Eagle's medium containing 
5% fetal bovine serum. 
 
The virulent ASFV isolates Lisbon-57 (I serotype), Kongo-73 (II serotype), Mozambique-79 (III 
serotype), France-64/32 (IV serotype), Magadi (VII serotype) were obtained in 1968-1986 from different 
ASFV outbreaks. These ASFV isolates were passaged no more than 2-5 times in leukocyte or primary 
porcine blood macrophage cell cultures prior to nucleotide sequencing. 
 
The avirulent ASFV strains Kat-350 (I serotype), KK-262 (II serotype), ɆɄ-200 (III serotype) and 
FɄ-135 (IV serotype) were obtained by the adaptation of wild-type viruses to CV-1, Vero and PPK-66b 
cell cultures. 
2.2. DNA sequencing and computer analysis 
The DNA templates used for the amplification reactions were obtained either from peripheral blood of 
infected pigs, for the wild-type viruses, or from supernatants of infected cell cultures, for tissue culture 
adapted viruses. Resulting PCR products were cloned into pTZ57R/T. The cloned p54 genes were 
sequenced by the dideoxynucleotide chain terminator method. 
Computer analysis of p54 gene sequences of different ASFV field isolates and reference strains from 
GenBank was performed using the software package BioEdit 6.0. 
2.3. Construction of p54, p30 and p12 expression plasmids 
The amplification was carried out with the following primers:  
 
x p54: 5'-GCGCGCGAATTCATGGATTCTGAATTTTTTCAACC-3' and  
             5'-GCGCGCGGATCCGTAGCTAATAAGCTCTGAG-3' [ 11 ]; 
 
x p30: 5'-AGAGGTTGAAGATCCATGGTTACCCATT-3' and 
             5'-CTAATAAATCTGGATCCTGCTGCTGCAG-3' [ 11 ]; 
 
x p12: 5'-GCGGATCCTTGAATAAGCGTTAAC-3' and
             5'-GCGGATCCGACATCATTATGGATGA-3' [ 2 ]. 
 
The PCR products were digested with EcoRI and BamHI (p54), NcoI and BamHI (p30), EcoRI and 
XbaI (p12), and then cloned into the polylinker region of pET 32b digested with corresponding enzymes. 
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All recombinant proteins were accumulated at E.coli cells strain BL pLyss. The expressed recombinant 
proteins were partially purified by Ni-charged chromatography [ 14 ]. The antigenic specificity of 
recombinant proteins was confirmed by ELISA with the purified specific hyper immune serum. 
2.4. Generation of a p30, p12 and p54-specific antiserum 
Recombinant proteins were used to raise a hyper immune rabbit antiserum. For the first inoculation, 
200μg/dose of the recombinant proteins mixed with complete Freund's adjuvant was inoculated 
intramuscularly. A second develop inoculation 14 days later was done with the same amount of the 
proteins mixed with incomplete Freund's adjuvant. 
 
Finally, a third dose of the recombinant proteins was inoculated 2 weeks later and the rabbit was bled. 
The antiserum obtained showed titers of antibodies higher than 1:2,000 in ELISA. These antiserum were 
used for the inhibition of haemoadsorption reaction. The reaction of haemoadsorption inhibition was 
performed on the primary porcine blood macrophage cell cultures without fetal bovine serum. After 
inoculation of 10-3TCID50 ASFV per cell, a monolayer was gently washed twice and different dilutions 
of rabbit antiserum in Dulbecco's modified Eagle's medium containing 5% were added. The inhibition of 
heamoadsorption was observed for 10 days and the presence of the virus reproduction was controlled by 
PCR. Similar experiments were carried out in the presence of specific anti-p30, -p54,-p12 or anti-ASFV 
serum. 
2.5. The protection from challenge. 
To analyze the serotype-specific immune response groups of pigs were immunized with the different 
avirulent ASFV strains. Pigs were inoculated of 103TCID50 ASFV per pig with attenuated different 
serotype ASFVs. 
3. Results 
Several factors have limited progress in the design of a vaccine against ASF virus. One of the most 
important is the lack of knowledge of ASFV serotypes.  
 
Serotype-based classification of ASFV strains was previously developed at our institute. Balyshev V. 
et al. (1999) [ 3 ] classified all ASFV strains in ten groups including eight serotype-based groups, one 
group of non-serotyped strains and one group consisting of heterogeneous isolates (Fig. 2). This 
classification is based on serotype-specific protective immunity to ASFV [ 16 ]. 
 
To induce protective immune responses to ASFV it is essential to know which serotype this strain 
belongs to [ 10 ]. We developed an experimental pig inoculation with 103TCID50 of attenuated different 
serotypes ASFVs induced protection against ASFV infection by the same serotype strains only and there 
was no protection from other group members. At day 21 after the immunization all pigs were challenged 
intramuscularly with 102TCID50 of the highly virulent virus isolates. Clinical signs of ASF such as fever, 
anorexia, lethargy, recumbency, and cyanosis were monitored daily. 
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Fig. 2. Serotype classification of ASFV isolates.
Mortality among control group animals was 100% on post inoculation days 7 or 9.  In contrast, solid 
protective immunity to highly virulent virus isolates challenge was observed in all recovered pigs. 
Animals remained clinically normal following challenge, with no fever or detectable viremia (see table 
1). 
 
Table 1. Serotype-specific protection different ASFV strains observed in pigs. 





1 Kat-350 (I serotype) Lisbon-57 (I serotype) 5/5 (100%) 0/5 
2 KK-262 (II serotype) Kongo-73 (II serotype) 10/10 (100%) 0/10 
3 ɆɄ 200 (III serotype) Mozambique-79 (III serotype) 6/6 (100%) 0/6 
4 FɄ-135 (IV serotype) France-64/32 (IV serotype) 16/16 (100%) 0/16 
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In this study, we made an attempt to identify which structural viral protein (p54, p30 and p12) 
determines ASFV serotype. The comparisons of the nucleotide sequences of the genes coding for p54, 
p30 and p12 of different virus isolates demonstrated that p30 gene was conserved among many isolates, 
whereas sequences p54 and p12 of the gene were highly variable in length and contained direct repeats in 
tandem that may account for the deletions found in different isolates.  
 
We observed different effects of anti-p54, anti-p12 or anti-p30 rabbit sera on virus replication in vitro. 
These experiments were performed in the presence of a normal nonimmune rabbit or control pig serum 
and in the presence of anti-p54 or -p30 sera or hyper immune serum. Antibodies to the highly variable 
immunodominant protein p54 inhibited haemoadsorption of ASFVs belonging to the same serotype group 
only, and did not inhibit haemoadsorption of ASFVs of other serotype ASFV (data not shown).
Table 2. Reaction inhibition haemadsorption of ASFV. 
ʋ 
Rabbit p30-antiserum dilution 
(Rec-p30 Magadi strain) 
Day 
3 4 5 6 7 8 9 10 
1  1:2 -  -  -  -  -  -  -  +†  
2  1:4 -  -  -  -  -  +  +  +  
3  1:8 -  -  -  +  +  +  +  +  
4  1:16 -  +  +  +  +  +  +  +  
5  1:32 +  +  +  +  +  +  +  +  
6  Swine specific antiserum VII serotype -  -  -  -  -  -  -  -  
7  Swine specific antiserum II serotype -  -  +  +  +  +  +  +  
 
Antibodies against ASFV protein p12 did not block virus binding to susceptible cells or  did not 
neutralized virus (data not shown). The serum of rabbits immunized with p30 (Magadi strain) proteins 
reduced or inhibited the reproduction of ASFV strains from different group in vitro (see table 2). The 
inhibition of haemoadsorption was observed for 10 days and the presence of the virus reproduction was 
monitored by PCR. The Fig. 3 demonstrated results of PCR assays. 
 
 
Fig. 3. Ihibition of ASFV reproduction in the presence of anti ASFV-p30 rabbit sera. 1-7 – propagation of DNA of ASFV from 1 to 
10-6 (with serum of rabbits to recombinant ɪ30); 8-14 – propagation of DNA of ASFV from 1 to 10-6 (without serum of rabbits to 
recombinant ɪ30), Ɇ – Gene Ruler 100bp DNA Ladder (Fermentas), K- - negative control. 
 
 
† Availability of  cytopathogenic effects. 
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We have determined the nucleotide sequence of the gene encoding highly immunogenic ASFV protein 
p54 (Magadi strain). Computer analysis of DNA sequences gene of p54 different ASFV field isolates 
deposited in GenBank was performed using the package BioEdit 6.0. The comparison of amino acids 
consecutions indicated their distribution according of serotype classification of ASFV isolates and strains 
developed at our institute. 
 
 
Fig. 4. Results of amino acids consecutions alignment p54 different ASFV field isolates and strains. (Multiple amino acid sequence 
alignment of p54 ASFV (ASFV, E183R gene) different serotype group (I, II, III, IV, VII). The relative similarity of residues at each 
position as well as the amino acid background coloring is shown according to Clustal_X codes).‡ 
 
4. Summary 
All investigations of ASFV immunity determined his critical points. By now ASFV virulence and host 
range genes have been identified and characterized. Live-attenuated ASF viruses protect against 
homologous viral challenge and ASF vaccination in endemic areas (regional) may be possible. Barderas 
M.G. et al. (2001) [ 4 ] have appointed the role protein p54 and p30 in the protective immune response. 
The immunized p54 and p30 pigs were protected from virus challenge. 
 
To induce protective immune responses to ASFV it is essential to know which serotype this strain 
belongs to. The protective immunity to homologous serotype viral strain in pigs surviving infection but 
cross-protective immunity has proven to be difficult to achieve. Anti-viral antibodies reduce or inhibit the 
reproduction ASF virus strains in vitro and are sufficient to protect pigs from disease. 
 
We had compared our serotype-based classification of ASFV strains, serotype-specific protection by 
avirulent viruses and ASFV p54 and p30 nucleic consecutions. The comparisons of the nucleotide 
sequences of the genes coding for p54 and p30 of different virus isolates demonstrated that p30 gene was 
conserved among many isolates, whereas sequences p54 of the gene was highly variable. The alignment 
analyze p54 genes demonstrated full correspondence our serotype-based classification with distribution of 
the nucleotide sequences different of ASFV strains.  
 
Antibodies to the highly variable immunodominant protein p54 inhibited haemoadsorption of ASFVs 
belonging to the same serotype group only, and did not inhibit haemoadsorption of ASFVs of other 
serotype ASFV. The serum of rabbits immunized with p30 (Magadi strain) proteins reduced or inhibited 
the reproduction of ASFV strains from different group in vitro. 
 
‡ Nucleotide sequences of p54 ASFV NVL-1, KK-262 and Magadi strain are yet not published in GeneBank. 
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Therefore the protective immunity against ASFV has serotype-specific character and the highly 
variable immunodominant ASFV p54 is one of the virus proteins responsible for serotype specificity. 
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